Extracted from this filing and checked against the source text.
Governance Changes
SEC 8-K Item 5.03/5.05/5.06
confidence 0.9
Biofrontera Inc.: Filed Certificate of Designation for Series B Preferred Stock, establishing rights, preferences, and limitations of three new series of preferred stock (effective 2024-02-20).
- Change
- charter amendment
- Effective
- 2024-02-20
Exact text from the filing
on February 20, 2024, the Company filed the Certificate of Designation with the Delaware Secretary of State designating 6,586 shares of its authorized and unissued preferred stock as Series B-1 Preferred Stock, 6,586 shares as Series B-2 Preferred Stock and 8,000 shares as Series B-3 Convertible Preferred Stock
View on SEC.gov
Material Agreements
SEC 8-K Item 1.01/1.02
confidence 0.97
Biofrontera Inc. entered into Securities Purchase Agreement with accredited investors (Preferred Investors) valued at $8,000,000 (effective 2024-02-19).
- Action
- entry
- Agreement
- equity purchase
- Counterparty
- accredited investors (Preferred Investors)
- Value
- $8,000,000
- Effective
- 2024-02-19
Exact text from the filing
On February 19, 2024, the Company entered into a securities purchase agreement (the “ Purchase Agreement ”) with certain accredited investors (the “ Preferred Investors ”), pursuant to which the Company agreed to issue and sell, in a private placement (the “ Offering ”), (i) 6,586 shares of Series B-1 Convertible Preferred Stock, par value $0.001 per share (the “ Series B-1 Preferred Stock ”), and (iii) warrants (the “ Preferred Warrant ”) to purchase shares of Series B-3 Convertible Preferred Stock, par value $0.001 per share (the “ Series B-3 Preferred Stock ”) for an aggregate offering price of $8.0 million.
View on SEC.gov